Kyverna
Kyverna to seek FDA engagement after positive autoimmune CAR-T data in stiff person syndrome
Kyverna; KYV-101; CAR-T; autoimmune disease; stiff person syndrome; SPS; FDA; regulatory path; cell therapy
Kyverna Therapeutics Cuts 16% of Staff in Q1 2025 Amid Pipeline Focus
Kyverna Therapeutics; layoffs; biotech; staff reduction; Q1 2025; CAR-T; autoimmune diseases; pipeline development; KYV-101
Kyverna’s CAR-T Relapse in Lupus Dents Autoimmune Hopes Amid Biotech Gold Rush
Kyverna, CAR-T, Lupus, Autoimmune Disease, Biotech, Gold Rush, Relapse, Clinical Trials, Gene Therapy